Xilio Therapeutics
30 hedge funds and large institutions have $13.5M invested in Xilio Therapeutics in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 8 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
49% more capital invested
Capital invested by funds: $9.03M → $13.5M (+$4.44M)
1.03% less ownership
Funds ownership: 4.26% → 3.23% (-1%)
9% less funds holding
Funds holding: 33 → 30 (-3)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$233K |
| 2 |
Morgan Stanley
New York
|
+$65.2K |
| 3 |
Millennium Management
New York
|
+$27.5K |
| 4 |
Renaissance Technologies
New York
|
+$27.4K |
| 5 |
SFG
SevenBridge Financial Group
Harrisburg,
Pennsylvania
|
+$21.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$1.22M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$982K |
| 3 |
AG
Artal Group
Luxembourg
|
-$248K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$64.3K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$58.2K |
XLO Hedge Fund Activity: Q1 2024 in Review
30 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2024, worth a combined $13.5M — up 49% from $9.03M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of XLO and 6 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $233K. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $1.22M.
- 30 institutional investors held Xilio Therapeutics (XLO) as of Q1 2024, down from 33 in Q4 2023.
- Funds reported $13.5M of Xilio Therapeutics stock for Q1 2024, up 49% quarter-over-quarter.
- 6 funds opened new Xilio Therapeutics positions in Q1 2024 and 8 closed out, a net change of -2 holders.
- The largest Xilio Therapeutics buyer in Q1 2024 was Balyasny Asset Management, an estimated $233K added.
- The largest Xilio Therapeutics seller in Q1 2024 was Atlas Venture Life Science Advisors, an estimated $1.22M sold.
Based on aggregated 13F filings for Q1 2024.